An investigation of physicians' prescribing behaviors related to antidiabetic agents for Type 2 diabetes mellitus patients and associated factors in Taiwan

References

• International Diabetes Federation. IDF diabetes atlas. 9th ed. Brussels: International Diabetes Federation; 2019.
   Google Scholar
• Sheen YJ, Hsu CC, Jiang YD, et al. Trends in prevalence and incidence of diabetes mellitus from 2005 to 2014 in Taiwan. J Formosan Medical Assoc. 2019;118:S66–S73.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Guidance for industry on diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes; availability; 2020 [cited 2020 Dec 30]. Available from: https://www.federalregister.gov/documents/2008/12/19/E8-30086/guidance-for-industry-on-diabetes-mellitus-evaluating-cardiovascular-risk-in-new-antidiabetic
   Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet (London, England. 2019;394(10193):121–130.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
   PubMed Web of Science ®Google Scholar
• Alharbi NS, Alanazi MA. Perceptions of health care professionals towards clinical practice guidelines: the case of diabetes mellitus in Saudi Arabia. Prim Care Diabetes. 2020;14(6):605–609.
   PubMed Web of Science ®Google Scholar
• Papanas N, Elisaf M, Kotsa K, et al. Adherence to the national guidelines for follow-up protocol in subjects with type 2 diabetes mellitus in Greece: the GLANCE study. Diabetes Ther. 2020;11(12):2887–2908.
   PubMed Web of Science ®Google Scholar
• Lu J, Zhao W, Chen T, et al. Influence of guideline adherence and parameter control on the clinical outcomes in patients with diabetic nephropathy. BMJ Open Diabetes Res Care. 2020;8(1):e001166.
   Web of Science ®Google Scholar
• Al-Areefi MA, Hassali MA, Ibrahim M. The role of pharmaceutical marketing and other factors in prescribing decisions: the Yemeni experience. Res Social Adm Pharm. 2013;9(6):981–988.
   PubMed Web of Science ®Google Scholar
• Davari M, Khorasani E, Tigabu BM. Factors influencing prescribing decisions of physicians: a review. Ethiop J Health Sci. 2018;28(6):795–804.
   PubMed Web of Science ®Google Scholar
• Murayama H, Imai K, Odawara M. Factors influencing the prescribing preferences of physicians for drug-naive patients with type 2 diabetes mellitus in the real-world setting in Japan: Insight from a web survey. Diabetes Ther. 2018;9(3):1185–1199.
   PubMed Web of Science ®Google Scholar
• Sharifnia SHA, Mohammadzadeh M, Arzani G, et al. Main factors affecting physicians' prescribing decisions: the Iranian experience. Iran J Pharm Res. 2018;17(3):1105–1115.
   PubMed Web of Science ®Google Scholar
• Altawalbeh SM, Ibrahim IA, Al-Shatnawi SF. Influence of pharmaceutical promotion on prescribers in Jordan. Int J Clin Pharm. 2020;42(2):744–755.
   PubMed Web of Science ®Google Scholar
• Economic Research Institute. Medical doctor salary in Taiwan [cited 2022 May 28]. Available from: https://www.erieri.com/salary/job/medical-doctor/taiwan
   Google Scholar
• Dennis JM, Henley WE, McGovern AP, et al. Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: a retrospective analysis of primary care data, 2010–2017. Diabetes Obes Metab. 2019;21(7):1576–1584.
   PubMed Web of Science ®Google Scholar
• Dave CV, Schneeweiss S, Wexler DJ, et al. Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013–2018. Diabetes Care. 2020;43(4):921–924.
   PubMed Web of Science ®Google Scholar